Healthcare Utilization and Costs Among Hospitalized Patients With Cardiomyopathy

Cardiomyopathy is the most common inherited cardiovascular disease, showing family aggregation, and it has a huge psychological and economic burden on family members. In this study, the investigators collected clinical information and costs of patients hospitalized with cardiomyopathy and establish a database to characterize real-world cost profile and inform cost management of cardiomyopathy.

Study Overview

• Status: Completed
• Conditions: Cardiomyopathies; Cost

Detailed Description

This study conducted a retrospective survey of hospitalized patients with cardiomyopathy aged ≥18 years in 13 centers in China from March 1, 2017 to March1, 2022. The investigators collected clinical information, healthcare utilization and cost data of patients hospitalized with cardiomyopathy so as to characterize real-world cost profile and inform cost management of cardiomyopathy in China.

• Study Type: Observational
• Enrollment (Actual): 15764

Contacts and Locations

Study Locations

• China
  • Beijing, China
    • Fuwai hospital, Beijing, Beijing 100037

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients hospitalized with cardiomyopathy as the primary discharge diagnosis are recruited retrospectively from multiple centers in China between March 1, 2017 and March 1, 2022.

Description

Inclusion Criteria:

• Hospitalized patients with primary discharge diagnosis meeting one of the following subtypes of cardiomyopathy were enrolled, including HCM, DCM, ACM, RCM, left ventricular non-compaction, cardiac amyloidosis, Fabry disease, Pompe disease, Danon disease, and PRKAG2 cardiac syndrome.

Exclusion Criteria:

• Records with a "likely" or "probable" diagnosis of cardiomyopathy were excluded.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
total cost per hospital admission	Total cost per hospital admissionin is total expenditures made towards a given hospital admission, including the portion paid by the health plan and any out-of-pocket costs paid by enrollees under the plan's cost sharing.The composition of the total cost of hospitalization by categorizing itemized costs into the following groups: total medical consumables cost, total diagnosis-related cost, total treatment cost (e.g., cost of operation), total Western medicine cost, total services cost, total blood and blood products cost, total traditional Chinese medicine cost, total traditional Chinese treatment cost, total rehabilitation cost, and other costs.	through hospitalization completion, an average of 10 days

Collaborators and Investigators

• Sponsor: China National Center for Cardiovascular Diseases

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2017
• Primary Completion (Actual): March 1, 2022
• Study Completion (Actual): February 1, 2026

Study Registration Dates

• First Submitted: September 27, 2024
• First Submitted That Met QC Criteria: March 23, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): May 20, 2026
• Last Update Submitted That Met QC Criteria: May 18, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Heart Diseases; Cardiomyopathies
• Other Study ID Numbers: 2023-ZX005

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No